Search the Newsreel

Silence Therapeutics (SLN): Invus and Avicenna entities report 7.0% stake via Debbane

Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP have filed an updated ownership report for Silence Therapeutics plc (SLN). As of June 30, 2026, entities related to Invus beneficially held 6.1% of ordinary shares, and Avicenna-related entities held 0.9%, with Raymond …

Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing

This funding roundup highlights recent financial activities in the biotech sector, with Silence Therapeutics and AbCellera launching public offerings, and Beyang Therapeutics and Remepy closing oversubscribed Series A financing rounds. Silence Therapeutics priced its IPO at $13.50 per ADS, expecting to raise approximately $175 …

Silence Therapeutics Plc (SLN) Stock Price | Live Quotes & Charts | NASDAQ

Silence Therapeutics Plc - American Depository Share (SLN) Stock Price, News, Quote & History

This page provides detailed stock information for Silence Therapeutics Plc (SLN), including its current price, daily changes, market capitalization, and key financial metrics. It also features recent news and press releases, highlighting the company's financial announcements, clinical trial results for its RNA interference therapies, …

Silence Therapeutics Announces Major ADS Public Offering

Silence Therapeutics (SLN) has priced a public offering of 12,962,963 American Depositary Shares (ADS) at $13.50 each, aiming to raise approximately $164 million, with an option for an additional $24.7 million. This capital raise is intended to strengthen the company's financial position and support …

Silence Therapeutics (SLN) prices $175M ADS sale at $13.50 per share

Silence Therapeutics plc announced the pricing of an underwritten public offering of 12,962,963 American Depositary Shares (ADSs) at $13.50 per ADS, expecting gross proceeds of approximately $175 million. The company has granted underwriters a 30-day option to purchase an additional 1,944,444 ADSs. The offering …

Silence Therapeutics Prices 12.96M ADS Offering at $13.50; Estimated Net Proceeds $164M

Silence Therapeutics has announced a public offering of 12,962,963 American Depositary Shares (ADS) at $13.50 per share, aiming to raise approximately $164.0 million in net proceeds. Underwriters, including Jefferies and Morgan Stanley, have a 30-day option to purchase an additional 1,944,444 ADSs, which could …

Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?

Silence upsizes USD 175m offering after divesiran Phase II win

Silence Therapeutics plc announced an upsized public offering, raising $175 million to fund the Phase III development of its lead siRNA asset, divesiran. This follows positive Phase II data for divesiran in polycythemia vera, showing an 88% clinical response rate. The company also has …

Why is Silence Therapeutics stock sliding today?

Silence Therapeutics prices upsized $175M ADS offering at $13.50 each

* Silence Therapeutics (SLN [https://seekingalpha.com/symbol/SLN]) priced an upsized underwritten public offering of 12.96M ADSs at $13.50 each, raising ~$175M in gross proceeds. * The underwriters have a 30-day option to purchase up to an additional 1.94M ADSs at the offering price. * The offering …

Morgan Stanley maintains Overweight rating on Silence Therapeutics (SLN:NASDAQ)

Morgan Stanley has reiterated its "Overweight" rating on Silence Therapeutics (SLN) following promising Phase 2 results for divesiran, its treatment for polycythemia vera. Analysts upgraded the price target from $25 to $32 per share due to the drug's potential "best-in-class" efficacy and robust safety …

Silence Therapeutics earnings beat by $0.05, revenue fell short of estimates

Silence Therapeutics Announces Public Offering Worth $150 Mln In American Depositary Shares

(RTTNews) - Silence Therapeutics plc (SLN), a biotechnology company, announced a proposed public offering for $150 million worth of American Depositary Shares (ADSs). Each ADS represents £0.05 in capital of the company in the U.S. Underwriters will also be offered a 30-day option to …

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow (NASDAQ:SLN)

Silence Therapeutics plc has published a slide deck discussing the top-line results from its SANRECO Phase II trial of Divesiran for Polycythemia Vera. The company's recent Q2 2026 earnings report showed an EPS miss of $0.16 at -$0.27 and revenue of $0.00, missing by …

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics launches $150 million public offering

Silence Therapeutics plc announced the commencement of an underwritten public offering in the United States, aiming to raise approximately $150 million through American Depositary Shares (ADSs). The offering includes a 30-day option for underwriters to purchase an additional 15% of ADSs. The clinical-stage biotechnology …

Silence Therapeutics Plans Underwriters' Option: Up to 15% More Depositary Shares

Silence Therapeutics plc has announced an underwritten public offering of approximately $150 million in American Depositary Shares (ADSs). The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total ADSs offered. Jefferies, Morgan Stanley, …

Silence Therapeutics stock surges as divesiran trial results fuel optimism (SLN:NASDAQ)

Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data

Silence Therapeutics (SLN) stock has seen a significant surge, rising by over 40% due to investor optimism surrounding promising clinical trial progress. Traders are closely watching the upcoming SANRECO Phase 2 topline data for divesiran in polycythemia vera, which is expected to be a …

Silence Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Silence Therapeutics Reports Positive Phase 2 Divesiran Data

Silence Therapeutics announced positive topline data from its Phase 2 SANRECO trial for divesiran, an siRNA therapy for polycythemia vera. The trial demonstrated an 88% clinical response rate, significant reduction in phlebotomy rates, and a favorable safety profile. These strong results position divesiran for …

Silence Therapeutics (NASDAQ:SLN) Issues Earnings Results

Silence Therapeutics plc Q2 2026: Revenue $0M, Net loss $12.3M, EPS ($0.09) — 10-Q Summary

Silence Therapeutics plc reported its Q2 2026 financial results, showing $0M in revenue and a net loss of $12.3M, an improvement from the prior year. The diluted loss per share was $0.09. Key business highlights include completing dosing for a Phase 2 trial, preparing …

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

Silence Therapeutics announced positive topline results from its Phase 2 SANRECO trial for divesiran, an siRNA therapy for polycythemia vera (PV). The trial met its primary and secondary endpoints, with divesiran showing an 88% response rate compared to 19% for placebo, effectively controlling hematocrit …

Silence Therapeutics (SLN) halves losses and funds operations into 2028 in Q2 update

Silence Therapeutics (SLN) halves net loss and boosts cash in Q2 2026

Silence Therapeutics Finishes Dosing 48 Patients in Blood Disorder Trial

Silence Therapeutics shares surge ahead of divesiran Phase 2 results call

Researcher looking through microscope ©Adobe Stock Images Silence Therapeutics (NASDAQ:SLN) shares jumped 16.2% in pre-market trading on Monday as investors positioned ahead of a conference call covering topline results from the Phase 2 SANRECO trial of divesiran, the company's lead siRNA candidate for polycythemia …

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Silence Therapeutics plc will host a conference call and webcast on Monday, August 10, 2026, at 8:00 a.m. EDT to discuss topline results from its Phase 2 SANRECO trial of divesiran for polycythemia vera (PV). The company, a clinical-stage biotechnology firm, specializes in developing …

Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year High - Still a Buy?

Silence Therapeutics (SLN) Drops 9.7% as Bearish Momentum Persists - Take Profit Levels

Silence Therapeutics (SLN) to Post Earnings on Thursday